Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis
- PMID: 27599725
- DOI: 10.1136/bmj.i4482
Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis
Abstract
Objective: To quantify the association between atrial fibrillation and cardiovascular disease, renal disease, and death.
Design: Systematic review and meta-analysis.
Data sources: Medline and Embase.
Eligibility criteria: Cohort studies examining the association between atrial fibrillation and cardiovascular disease, renal disease, and death. Two reviewers independently extracted study characteristics and the relative risk of outcomes associated with atrial fibrillation: specifically, all cause mortality, cardiovascular mortality, major cardiovascular events, any stroke, ischaemic stroke, haemorrhagic stroke, ischaemic heart disease, sudden cardiac death, congestive heart failure, chronic kidney disease, and peripheral arterial disease. Estimates were pooled with inverse variance weighted random effects meta-analysis.
Results: 104 eligible cohort studies involving 9 686 513 participants (587 867 with atrial fibrillation) were identified. Atrial fibrillation was associated with an increased risk of all cause mortality (relative risk 1.46, 95% confidence interval 1.39 to 1.54), cardiovascular mortality (2.03, 1.79 to 2.30), major cardiovascular events (1.96, 1.53 to 2.51), stroke (2.42, 2.17 to 2.71), ischaemic stroke (2.33, 1.84 to 2.94), ischaemic heart disease (1.61, 1.38 to 1.87), sudden cardiac death (1.88, 1.36 to 2.60), heart failure (4.99, 3.04 to 8.22), chronic kidney disease (1.64, 1.41 to 1.91), and peripheral arterial disease (1.31, 1.19 to 1.45) but not haemorrhagic stroke (2.00, 0.67 to 5.96). Among the outcomes examined, the highest absolute risk increase was for heart failure. Associations between atrial fibrillation and included outcomes were broadly consistent across subgroups and in sensitivity analyses.
Conclusions: Atrial fibrillation is associated with an increased risk of death and an increased risk of cardiovascular and renal disease. Interventions aimed at reducing outcomes beyond stroke are warranted in patients with atrial fibrillation.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Comment in
-
Atrial Fibrillation Increases Risk of CVD, Renal Disease, Death.Am J Nurs. 2017 Apr;117(4):66. doi: 10.1097/01.NAJ.0000515238.82289.81. Am J Nurs. 2017. PMID: 28333749 No abstract available.
Similar articles
-
Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies.BMJ. 2016 Jan 19;532:h7013. doi: 10.1136/bmj.h7013. BMJ. 2016. PMID: 26786546 Free PMC article.
-
Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis.Eur J Prev Cardiol. 2017 Sep;24(14):1555-1566. doi: 10.1177/2047487317715769. Epub 2017 Jun 15. Eur J Prev Cardiol. 2017. PMID: 28617620 Free PMC article.
-
Atrial fibrillation is associated with sudden cardiac death: a systematic review and meta-analysis.J Interv Card Electrophysiol. 2018 Mar;51(2):91-104. doi: 10.1007/s10840-017-0308-9. Epub 2018 Jan 13. J Interv Card Electrophysiol. 2018. PMID: 29332241
-
Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.PLoS One. 2018 Mar 8;13(3):e0193924. doi: 10.1371/journal.pone.0193924. eCollection 2018. PLoS One. 2018. PMID: 29518134 Free PMC article.
-
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.Cochrane Database Syst Rev. 2017 Nov 6;11(11):CD011373. doi: 10.1002/14651858.CD011373.pub2. Cochrane Database Syst Rev. 2017. PMID: 29105079 Free PMC article.
Cited by
-
Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial.BMJ Open. 2021 Mar 31;11(3):e044744. doi: 10.1136/bmjopen-2020-044744. BMJ Open. 2021. PMID: 33789853 Free PMC article.
-
Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial.JAMA. 2021 Mar 16;325(11):1061-1073. doi: 10.1001/jama.2021.1489. JAMA. 2021. PMID: 33724323 Free PMC article. Clinical Trial.
-
Higher-Order Spectral Analysis Combined with a Convolution Neural Network for Atrial Fibrillation Detection-Preliminary Study.Sensors (Basel). 2024 Jun 27;24(13):4171. doi: 10.3390/s24134171. Sensors (Basel). 2024. PMID: 39000950 Free PMC article.
-
Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program.PLoS One. 2022 Oct 6;17(10):e0274237. doi: 10.1371/journal.pone.0274237. eCollection 2022. PLoS One. 2022. PMID: 36201473 Free PMC article.
-
Cardiovascular medications used for comorbid diseases in patients with atrial fibrillation. The JoFib study.Eur J Clin Pharmacol. 2024 Apr;80(4):545-552. doi: 10.1007/s00228-024-03622-8. Epub 2024 Jan 23. Eur J Clin Pharmacol. 2024. PMID: 38253701
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical